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E V I D E N C E - B A S E D A N S W E R
Lifestyle modification clearly works; 
medication may have a role as well
While lifestyle interventions are clearly efficacious,
clinicians will need appropriate resources to help
patients exercise and maintain weight loss if they are
to achieve similar results. This Clinical Inquiry helps
practitioners realize that diabetes mellitus, impaired
fasting glucose, impaired glucose tolerance, and
obesity probably constitute a spectrum disorder and
that we should treat all of these patients more
aggressively.  This is particularly true considering the
epidemic proportion of obesity in the United States.
Physicians’ attitudes towards obese patients might
be a barrier to effective care. It is important for 
clinicians to realize that monitoring hemoglobin A1c
levels is not recommended for IGT and IFG. Putting
evidence into practice will mean that physicians
need to be aware of the efficacy of both lifestyle 
and medical interventions in IGT and IFG. 
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The best treatment strategy for impaired glucose
tolerance (IGT) and impaired fasting glucose (IFG) 
is lifestyle intervention with a structured weight loss
program of diet and exercise (strength of 
recommendation [SOR]: B, based on high-quality
randomized controlled trials [RCTs] for disease-
oriented outcomes). Patients with IGT and IFG
should be counseled to lose 5% to 7% of their body
weight and instructed on moderate intensity 
physical activity for ~150 minutes per week. 
Metformin (Glucophage), acarbose (Precose),
and troglitazone (Rezulin) are also effective, but
lifestyle interventions appear superior (TABLE)
(SOR: B, based on single high quality randomized
controlled trials). The American Diabetes
Association defines IFG as a fasting glucose of
between 100 and 125 mg/dL, and IGT as glucose
between 140 and 199 mg/dL after a 2-hour oral glu-
cose challenge. 
Adults with IGT or IFG should have laboratory
screening for diabetes every 1 to 2 years (SOR: C,
based on expert opinion), using the fasting plasma
glucose (FPG) as a screening test (SOR: C, based
on expert opinion). For individuals whose FPG
exceeds 125 mg/dL, oral glucose tolerance testing
is considered superior to glycohemoglobin testing
for ruling out progression to diabetes (SOR: C,
based on expert opinion). 
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■ Evidence Summary
Both IGT and IFG are associated with a
significant risk of developing diabetes
and its associated cardiovascular comor-
bidities; thus, the primary goal for treat-
ment is to prevent or delay the onset of
diabetes. Recent well-designed studies
have demonstrated benefits of lifestyle
interventions for patients with IGT.
In the US Diabetes Prevention
Program (DPP), 3234 patients with IGT
and a body-mass index (BMI) of at least
24 kg/m2 were randomly assigned to one
of the following groups: placebo, met-
formin, or intensive lifestyle modifica-
tion. After an average follow-up of 2.8
years, there was a 14% absolute risk
reduction in the progression to diabetes
in the lifestyle intervention group com-
pared with placebo (number needed to
treat [NNT]=7).1 In the Finnish Diabetes
Prevention Study, the lifestyle interven-
tion group had a 12.5% absolute risk
reduction compared with the control
group (NNT=8).2 Successful lifestyle
interventions in these studies included
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FAST TRACK
weight loss of 5% to 7%, decreased fat
intake, increased fiber intake, and 150
minutes of exercise per week.1–2
Drug therapy with metformin, 
acarbose, and troglitazone has also been 
successful in preventing or delaying 
diabetes in people with IGT.1,3,4 In the
placebo-controlled DPP trial, metformin
use was associated with a reduction 
in progression to diabetes mellitus
(NNT=14).1 In the STOP-NIDDM trial
of 1429 persons over 3.3 years of follow-
up, acarbose 100 mg 3 times daily result-
ed in a 9% reduction of progression to
diabetes, compared with placebo
(NNT=11).3
In the TRIPOD study, troglitazone
use was associated with a 17% absolute
risk reduction in the incidence of diabetes
in high-risk Hispanic women (NNT=6
over an average of 30 months).4 The pre-
ventive effect of the drug was maintained
more than 8 months after troglitazone
therapy was discontinued (due to with-
drawal from the US market). Current tri-
als with other thiazolidinediones are
underway. 
■ Recommendations from others
The American Diabetes Association
(ADA) recommends counseling on weight
loss and instructing on increased physical
activity in people with IGT.5 The United
States Preventive Services Task Force rec-
ommends intensive programs of lifestyle
modification (diet, exercise, and behavior)
for patients who have pre-diabetes.6
The ADA recommends regular 
monitoring (every 1 to 2 years) for the
development of diabetes in people with
prediabetes, and prefers FPG to screen 
for diabetes since it is faster, cost-effec-
tive, and more reproducible than the
more sensitive 2-hour oral glucose 
tolerance test.5,7 The ADA also recom-
mends that if the FPG is <126 mg/dL and
there is a high suspicion for diabetes, a 
2-hour oral glucose tolerance test should
be performed.
Glycosylated hemoglobin (HbA1C) is
not recommended as a screening tool,
because individuals with IFG or IGT 
may have normal or near-normal HbA1C
levels; these individuals often manifest
hyperglycemia only when challenged with
T A B L E
RELATIVE RISK REDUCTION
IN INCIDENCE OF DIABETES NUMBER NEEDED ABSOLUTE
INTERVENTION MELLITIS (95% CI) TO TREAT RISK REDUCTION
Lifestyle1 58% (48%–66%) 7 14%
Lifestyle2 58% (hazard ratio 0.4; 8 12.5%
95% CI, 0.3%–0.7%)
Metformin 850 mg twice 31% (17%–43%) 14 7%
daily (Glucophage)1
Acarbose 100 mg three 25% (10%–37%) 11 9%
times daily (Precose)3
Troglitazone 400 mg 56% (17%–75%) 6 16.7%
daily4 (Rezulin 
[withdrawn])
NNT, number needed to treat; ARR, absolute risk reduction.
Adapted from Davies et al, Diabetic Medicine 2004.9
Comparison of major lifestyle 
and pharmacologic trials in IGT and IFG
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the oral glucose load use in the standard-
ized oral glucose tolerance test.8 
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■ What workup is required 
in the newly diagnosed 
hypertensive patient?
■ What is the best treatment 
for eczema unresponsive to mild
corticosteroid moisturizers?
■ What are the risks and benefits 
of progestin-only contraceptives?
■ Do thiazolidinediones increase risk
of heart failure in patients 
with diabetes?
■ What is the best approach 
to a solitary pulmonary nodule 
identified by chest x-ray?
■ What is the diagnostic approach 
to a patient with leg cramps?
■ When should you order 
a Lyme titer?
■ What are the most effective 
methods for managing 
psychosocial stress?
Look for these 
Clinical Inquiries
Coming soon in JFP
